"Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
| Descriptor ID |
D018501
|
| MeSH Number(s) |
D27.505.954.329
|
| Concept/Terms |
Antirheumatic Agents- Antirheumatic Agents
- Anti-Rheumatic Drugs
- Anti Rheumatic Drugs
- Antirheumatic Drugs
- Anti-Rheumatic Agents
- Anti Rheumatic Agents
Antirheumatic Drugs, Disease-Modifying- Antirheumatic Drugs, Disease-Modifying
- Antirheumatic Drugs, Disease Modifying
- DMARD
- Disease-Modifying, Antirheumatic Second-Line Drugs
- Disease Modifying, Antirheumatic Second Line Drugs
- Antirheumatic Disease-Modifying Second-Line Drugs
- Antirheumatic Disease Modifying Second Line Drugs
- Disease-Modifying Antirheumatic Drugs
- Disease Modifying Antirheumatic Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antirheumatic Agents".
This graph shows the total number of publications written about "Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 3 | 0 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 2 | 4 |
| 2016 | 1 | 2 | 3 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 5 | 1 | 6 |
| 2020 | 4 | 0 | 4 |
| 2021 | 4 | 0 | 4 |
| 2022 | 5 | 0 | 5 |
| 2023 | 3 | 0 | 3 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 0 | 2 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles.
-
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study. Ann Rheum Dis. 2026 Sep; 85(9):1879-1889.
-
Reassessing the prevalence of monophasic, polyphasic and persistent disease courses in still's disease. Semin Arthritis Rheum. 2026 Apr; 77:152928.
-
Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 06 01; 64(6):3434-3443.
-
Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One-Year Double-Blind, Randomized, Placebo-Controlled Trial Using High-Resolution Peripheral Quantitative Computed Tomography. Arthritis Rheumatol. 2025 08; 77(8):1015-1025.
-
Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk. JAMA Netw Open. 2024 11 04; 7(11):e2446336.
-
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024 Oct 21; 83(11):1561-1571.
-
Disease-Modifying Drugs for Adult-Onset Rheumatoid Arthritis. JAMA. 2024 03 26; 331(12):1055-1056.
-
JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul-Dec; 19(11):1385-1397.
-
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 11; 46(11):1049-1071.
-
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.